N-{5-Bromo-2-[4-(methylsulfanyl)phenoxy]benzyl}-N-methylamine | 364321-65-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{5-Bromo-2-[4-(methylsulfanyl)phenoxy]benzyl}-N-methylamine
• 英文别名: (5-bromo-2-(4-(methylthio)phenoxy)phenyl)-N-methylmethanamine；1-[5-bromo-2-(4-methylsulfanylphenoxy)phenyl]-N-methylmethanamine
• CAS: 364321-65-3
• 化学式: C₁₅H₁₆BrNOS
• 分子量: 338.268
• InChiKey: MFIMYVJYQZCFGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  46.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-{5-Bromo-2-[4-(methylsulfanyl)phenoxy]benzyl}-N-methylamine 、 二碳酸二叔丁酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 [5-bromo-2-(4-methylsulfanyl-phenoxy)-benzyl]-methyl-carbamic acid tert-butyl ester
  参考文献：
  名称：

  组胺H3拮抗剂和5-羟色胺再摄取抑制剂哌嗪和二氮杂环庚烷酰胺的合成及其生物学活性。

  摘要：

  描述了一系列新的哌嗪和二氮杂环庚烷酰胺的合成和生物活性。新化合物是高亲和力的组胺H3配体和5-羟色胺再摄取抑制剂。

  DOI：

  10.1016/j.bmcl.2007.11.016
• 作为产物：
  描述：

  在 sodium tetrahydroborate 作用下， 以 甲醇 、 水 为溶剂， 生成 N-{5-Bromo-2-[4-(methylsulfanyl)phenoxy]benzyl}-N-methylamine
  参考文献：
  名称：

  组胺H3拮抗剂和5-羟色胺再摄取抑制剂哌嗪和二氮杂环庚烷酰胺的合成及其生物学活性。

  摘要：

  描述了一系列新的哌嗪和二氮杂环庚烷酰胺的合成和生物活性。新化合物是高亲和力的组胺H3配体和5-羟色胺再摄取抑制剂。

  DOI：

  10.1016/j.bmcl.2007.11.016

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Diphenyl ether compounds useful in therapy
  申请人：——

  公开号：US20020052395A1

  公开（公告）日：2002-05-02

  A compound of general formula (I), or pharmaceutically acceptable salts, solvates or polymorphs thereof; wherein; R 1 and R 2 , which may be the same or different, are hydrogen, C 1 -C 6 alkyl, (CH 2 )m(C 3 -C 6 cycloalkyl) wherein m =0, 1, 2 or 3, or R 1 and R 2 together with the nitrogen to which they are attached form an azetidine ring; each R 3 is independently CF 3 , OCF 3 , C 1-4 alkylthio or C 1 -C 4 alkoxy; n is 1, 2 or 3; and R 4 and R 5 , which may be the same or different, are: A-X, wherein A =—CH=CH— or —(CH 2 )p— where p is 0, 1 or 2; X is hydrogen, F, Cl, Br, I, CONR 6 R 7 ,SO 2 NR 6 R 7 , SO 2 NHC(=O)R 6 , OH, C 1-4 alkoxy, NR 8 SO 2 R 9 , NO 2 , NR 6 R 11 , CN, CO 2 R 10 , CHO, SR 10 , S(O)R 9 or SO 2 R 10 R 6 , R 7 , R and R 10 which may be the same or different, are hydrogen or C 1-6 alkyl optionally substituted independently by one or more R 12 ; R 9 is C 1-6 alkyl optionally substituted independently by one or more R 12 ; R 11 is hydrogen, C 1-6 alkyl optionally substituted independently by one or more R 12 , C(O)R 6 , CO 2 R 9 , C(O)NHR 6 or SO 2 NR 6 R 7 ; R 12 is F, OH, CO 2 H, C 3-6 cycloalkyl, NH 2 , CONH 2 , C 1-6 alkoxy, C 1-6 alkoxycarbonyl or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O optionally substituted independently by one or more R 13 ; or R 6 and R 7 , together with the nitrogen to which they are attached, form a 4-, 5- or 6-membered heterocyclic ring optionally substituted independently by one or more R 13 ; or a 5- or 6-membered heterocyclic ring containing 1, 2 or 3 heteroatoms selected from N, S and O, optionally substituted independently by one or more R 13 ; wherein R 13 is hydroxy, C 1 -C 4 alkoxy, F, C 1 -C 6 alkyl, haloalkyl, haloalkoxy, —NH 2 , —NH(C 1 -C 6 alkyl) or —N(C 1 -C 6 alkyl) 2 ; wherein when R 1 and R 2 are methyl, R 4 and R 5 are hydrogen and n is 1, R 3 is not a —SMe group para to the ether linkage linking rings A and B. 1

  通用式（I）的化合物，或其药学上可接受的盐、溶剂化合物或多晶型；其中；R1和R2，可能相同或不同，为氢、C1-C6烷基、（CH2）m（C3-C6环烷基）其中m=0、1、2或3，或者R1和R2与它们连接的氮一起形成氮杂环丙烷环；每个R3独立地为CF3、OCF3、C1-4烷基硫或C1-C4烷氧基；n为1、2或3；以及R4和R5，可能相同或不同，为：A-X，其中A=-CH=CH-或-(CH2)p-其中p为0、1或2；X为氢、F、Cl、Br、I、CONR6R7、SO2NR6R7、SO2NHC(=O)R6、OH、C1-4烷氧基、NR8SO2R9、NO2、NR6R11、CN、CO2R10、CHO、SR10、S(O)R9或SO2R10R6，R7，R和R10可能相同或不同，为氢或C1-6烷基，可选地独立地被一个或多个R12取代；R9为C1-6烷基，可选地独立地被一个或多个R12取代；R11为氢、C1-6烷基，可选地独立地被一个或多个R12取代，C(O)R6，CO2R9，C(O)NHR6或SO2NR6R7；R12为F、OH、CO2H、C3-6环烷基、NH2、CONH2、C1-6烷氧基、C1-6烷氧羰基或含有1、2或3个异原子（N、S和O）的5-或6元杂环，可选地独立地被一个或多个R13取代；或R6和R7，与它们连接的氮一起，形成一个可选地被一个或多个R13取代的4、5或6元杂环；或含有1、2或3个异原子（N、S和O）的5-或6元杂环，可选地独立地被一个或多个R13取代；其中R13为羟基、C1-C4烷氧基、F、C1-C6烷基、卤代烷基、卤代烷氧基、-NH2、-NH(C1-C6烷基)或-N(C1-C6烷基)2；当R1和R2为甲基时，R4和R5为氢，n为1，R3不是SMe基固定在连接环A和B的醚键旁。
• Benzylamine histamine H3 antagonists and serotonin reuptake inhibitors
  作者：Michael A. Letavic、Emily M. Stocking、Ann J. Barbier、Pascal Bonaventure、Jamin D. Boggs、Brian Lord、Kirsten L. Miller、Sandy J. Wilson、Nicholas I. Carruthers

  DOI：10.1016/j.bmcl.2007.06.061

  日期：2007.9

  The design, synthesis, and in vitro activity of a series of novel 5-ethynyl-2-aryloxybenzylamine-based histamine H-3 ligands that are also serotonin reuptake transporters is described. (c) 2007 Elsevier Ltd. All rights reserved.
• DIPHENYL ETHER COMPOUNDS USEFUL IN THERAPY
  申请人：Pfizer Limited

  公开号：EP1268396B1

  公开（公告）日：2005-07-20
• Compositions and methods for treatment of viral diseases
  申请人：Johansen Lisa M.

  公开号：US20100092479A1

  公开（公告）日：2010-04-15

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E).